Afterload reduction with hydralazine following valve replacement.
Impedance reduction with hydralazine was evaluated in 23 patients 1 to 3 hours after aortic or mitral valve replacement. Patients were randomly assigned to Group 1 (0.25 mg/kg) or Group 2 (0.5 mg/kg) and responses at 20, 60, and 120 minutes compared with control (paired t test) and mean values for each group compared (t test). In Group 1 significant responses were the fall in mean arterial pressure (78.3 +/- 3.0 to 66.7 +/- 2.2 mm Hg) and systemic vascular resistance (2,808 +/- 264 to 1,823 +/- 164 dynes-sec/cm5); the increase in cardiac index (2.07 +/- 0.13 to 2.71 +/- 0.21 L/min/m2), stroke volume index (26.9 +/- 2.3 to 34.0 +/- 3.3 ml/beat), and heart rate (80.8 +/- 5.8 to 84.2 +/- 6.6 beats/min). Central venous pressure did not change and left atrial pressure decreased at 120 minutes. Group 2 responses were similar except for higher central venous pressure at 20 minutes, higher left atrial pressures at control, 20, and 60 minutes, and lower left ventricular stroke work at control, 20, and 60 minutes. By selectively dilating the arterial system, hydralazine reduces mean arterial pressure and systemic vascular resistance and increases cardiac output with suble filling pressures.
D001021:Aortic Valve / Q000601:surgery*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002496:Central Venous Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006350:Heart Valve Prosthesis; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D013318:Stroke Volume / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects*
D006830:Hydralazine